Stem Cell Therapy for Multiple Sclerosis: Where the Evidence Stands

ByFarhan Feroz Ali

Multiple sclerosis is the most important page on this site, because it is the one condition where the answer is substantially positive — and where confusing two very different treatments could cost you a great deal.

Two different things share the name

AHSCT — autologous haematopoietic stem cell transplantation. A hospital procedure. Chemotherapy is used to suppress the immune system, then the patient’s own previously collected haematopoietic stem cells are reinfused to rebuild it. The aim is to reset an immune system that is attacking the nervous system. This has real randomised evidence.

MSC infusion at a private clinic. An intravenous drip of mesenchymal stromal cells, typically $8,000–$25,000, marketed for MS among many other conditions. This does not have comparable evidence and is not the same treatment.

Clinics selling the second frequently cite research about the first. If a website discusses impressive MS outcomes and also offers the same infusion for knee arthritis and anti-ageing, it is not offering AHSCT.

What the evidence shows for AHSCT

Joint recommendations from ECTRIMS and the EBMT, published in 2024, drew on 26 contemporary studies from 2019–2024, two randomised controlled trials, and multiple meta-analyses.

Key findings:

  • In the MIST randomised trial, progression-free survival at five years was approximately 90% for AHSCT versus about 25% for continued disease-modifying therapy.
  • Across five comparative studies against alemtuzumab, AHSCT was superior on relapses, MRI activity, and NEDA (no evidence of disease activity).
  • Progression-free survival of 70–87% at 5–10 years in relapsing-remitting cohorts.
  • Selected patients under 45 with short disease duration and recent inflammatory activity showed near-complete progression-free survival.

This is among the strongest evidence in the entire stem cell field.

Who it is for

The consensus supports AHSCT primarily for:

  • Relapsing-remitting MS that has not responded to disease-modifying therapy, particularly after failure of a high-efficacy DMT
  • Rapidly evolving, severe treatment-naive MS — an emerging indication
  • Active secondary progressive MS, with some demonstrated benefit

The pattern that predicts response: younger patients, shorter disease duration, and active inflammation visible on MRI. AHSCT works by stopping immune attack. Where damage has already accumulated without ongoing inflammation, it has much less to offer, and it does not repair existing damage.

The risks are real

This is chemotherapy followed by transplantation, not an infusion.

  • Transplant-related mortality is approximately 0.3% in modern practice, improved from 3.6% before 2005.
  • Infection risk during the period of immune suppression
  • Infertility — sperm or egg banking should be discussed beforehand
  • Secondary autoimmune conditions
  • Weeks in hospital and months of recovery

The improvement in mortality reflects better patient selection and refined protocols at experienced centres. Where the procedure is done matters enormously.

Where AHSCT should be performed

At an experienced transplant centre with a neurology service, ideally one participating in EBMT registry reporting. The mortality figures above come from such centres. They should not be assumed to apply to a clinic offering "stem cell therapy for MS" without a transplant programme.

Coverage

Inconsistent. Some insurers cover AHSCT for aggressive relapsing MS with prior authorisation, documented DMT failure, and treatment at an approved centre. Many still classify it as investigational. Denials are genuinely appealable with strong documentation and a supportive neurologist — this is one of the few situations in this field where fighting an insurer is worth the effort.

What we would do

Talk to an MS neurologist at an academic centre about whether you meet AHSCT criteria. Search ClinicalTrials.gov for AHSCT trials. Ask directly whether your disease is still inflammatory, since that is what predicts benefit.

Be cautious with any private clinic offering an IV infusion for MS at a fraction of transplant cost. The price difference reflects a difference in the treatment, not a bargain.

Sources

  1. Autologous haematopoietic stem cell transplantation for MS and NMOSD — recommendations from ECTRIMS and the EBMT. Nature Reviews Neurology, 2024.
  2. Burt RK et al. Effect of non-myeloablative HSCT vs continued DMT on disease progression in relapsing-remitting MS (MIST trial). JAMA, 2019.
  3. Autologous Stem Cell Transplantation for Multiple Sclerosis. Transplantation and Cellular Therapy, 2025.

Not sure whether this is right for you?

Tell us about your condition and we will send you our free clinic-vetting checklist, an honest summary of the evidence for your situation, and — where they exist — free clinical trials you may be eligible for. Get matched with a vetted clinic

Medical disclaimer

This article is for general information and is not medical advice. We are not a healthcare provider and do not diagnose or treat any condition. Most stem cell treatments discussed here are not FDA approved for these uses, outcomes vary, and no result is guaranteed. Always speak with a licensed physician who knows your history. See our medical disclaimer and how we make money.

Similar Posts